BACKGROUND: Rhabdoid tumours (RTs) are aggressive malignancies of childhood, mainly occurring in the kidney and brain. We describe a national multi-centre retrospective analysis of extra-renal non-cranial RTs (ERRTs). PROCEDURE: Diagnosis relied on central histological review and/or on hSNF5/INI1 defect, evidenced by immunohistochemistry or molecular screening. Clinical data were obtained from physicians. RESULTS: Twenty six patients fulfilled the inclusion criteria. Median age at diagnosis was 28 months [0-366], including late childhood and young adults cases. Surgery, either initial or secondary, was complete in three. All but three patients received chemotherapy, with variable regimens. Additional radiotherapy was used in six patients. Median time to recurrence or progression was 5 months [0-44], and one patient remained free of disease at 7 years. CONCLUSIONS: ERRTs share the same chemosensitivity, early recurrence, and poor prognosis as renal and cerebral RTs. No chemotherapy regimen demonstrates a superior response. (c) 2008 Wiley-Liss, Inc.
BACKGROUND:Rhabdoid tumours (RTs) are aggressive malignancies of childhood, mainly occurring in the kidney and brain. We describe a national multi-centre retrospective analysis of extra-renal non-cranial RTs (ERRTs). PROCEDURE: Diagnosis relied on central histological review and/or on hSNF5/INI1 defect, evidenced by immunohistochemistry or molecular screening. Clinical data were obtained from physicians. RESULTS: Twenty six patients fulfilled the inclusion criteria. Median age at diagnosis was 28 months [0-366], including late childhood and young adults cases. Surgery, either initial or secondary, was complete in three. All but three patients received chemotherapy, with variable regimens. Additional radiotherapy was used in six patients. Median time to recurrence or progression was 5 months [0-44], and one patient remained free of disease at 7 years. CONCLUSIONS: ERRTs share the same chemosensitivity, early recurrence, and poor prognosis as renal and cerebral RTs. No chemotherapy regimen demonstrates a superior response. (c) 2008 Wiley-Liss, Inc.
Authors: Chandraiah Lagisetti; Alan Pourpak; Tinopiwa Goronga; Qin Jiang; Xiaoli Cui; Judith Hyle; Jill M Lahti; Stephan W Morris; Thomas R Webb Journal: J Med Chem Date: 2009-11-26 Impact factor: 7.446
Authors: Michael C Frühwald; Jaclyn A Biegel; Franck Bourdeaut; Charles W M Roberts; Susan N Chi Journal: Neuro Oncol Date: 2016-01-10 Impact factor: 12.300
Authors: Julia E Heck; Christina A Lombardi; Myles Cockburn; Travis J Meyers; Michelle Wilhelm; Beate Ritz Journal: Pediatr Blood Cancer Date: 2012-03-20 Impact factor: 3.167
Authors: Adam D Wolfe; Christian M Capitini; Shahriar M Salamat; Kenneth DeSantes; Kristin A Bradley; Tabassum Kennedy; Louis P Dehner; Neha J Patel Journal: J Pediatr Hematol Oncol Date: 2018-01 Impact factor: 1.289
Authors: Natasha Savage; Dan Linn; Colleen McDonough; Jeffrey M Donohoe; Arie Franco; Victor Reuter; Paul W Biddinger; Katherine W Eaton; Jaclyn A Biegel; Suash Sharma Journal: Ann Diagn Pathol Date: 2011-07-19 Impact factor: 2.090